Innovations in targeted drug delivery systems are actively reshaping the competitive landscape of the Non Muscle Invasive Bladder Cancer Market, offering refined clinical alternatives for complex patient cohorts. Historically, managing NMIBC has been challenging due to exceptionally high tumor recurrence and progression rates, which necessitate lifelong urological surveillance and repetitive...
Bangla